Literature DB >> 7992820

Inhibitory effects of sho-seiryu-to on acetylcholine-induced responses in nasal gland acinar cells.

K Ikeda1, D Z Wu, M Ishigaki, H Sunose, T Takasaka.   

Abstract

Sho-seiryu-to, a traditional Japanese herbal medicine, has been used extensively in the treatment of allergic rhinitis. The effects of Sho-seiryu-to on electrical responses induced by acetylcholine in dissociated nasal gland acinar cells were investigated using patch-clamp and microfluorimetric imaging techniques. The application of Sho-seiryu-to inhibited both K+ and Cl- currents augmented by acetylcholine. The elevation of intracellular Ca2+ and Na+ concentrations induced by acetylcholine was also inhibited by Sho-seriyu-to. These findings suggest that Sho-seiryu-to attenuated the secretion of water and electrolytes from the nasal glands through an anti-cholinergic effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7992820     DOI: 10.1142/S0192415X94000231

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  3 in total

1.  Evaluation of shoseiryuto for seasonal allergic rhinitis, using an environmental challenge chamber.

Authors:  Junya Kurita; Syuji Yonekura; Tomohisa Iinuma; Riyo Yoneda; Sakiko Imamoto; Toyoyuki Hanazawa; Yohei Kawasaki; Takao Namiki; Yoshitaka Okamoto
Journal:  World Allergy Organ J       Date:  2022-03-20       Impact factor: 4.084

2.  Proteomic Analysis of Anti-inflammatory Effects of a Kampo (Japanese Herbal) Medicine "Shoseiryuto (Xiao-Qing-Long-Tang)" on Airway Inflammation in a Mouse Model.

Authors:  Takayuki Nagai; Marino Nakao; Yuliko Shimizu; Yoshio Kodera; Masamichi Oh-Ishi; Tadakazu Maeda; Haruki Yamada
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-10       Impact factor: 2.629

3.  Complementary therapies in allergic rhinitis.

Authors:  Ibrahim Sayin; Cemal Cingi; Fatih Oghan; Bahadir Baykal; Seckin Ulusoy
Journal:  ISRN Allergy       Date:  2013-11-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.